Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Po-Hung Hsieh
Observed name:
Po‐Hung Hsieh
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
University of Chicago
ORCID:
0000-0003-1744-4815
Observed ORCID:
0000-0003-1744-4815
OpenAlex ID:
A5083546449
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings
2022
·
Po-Hung Hsieh
, Alec J. Kacew
, et al.
·
npj Breast Cancer
·
24
PDF
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions
2023
·
Sofia I. Jacobson
, Alec J. Kacew
, et al.
·
JCO Oncology Practice
·
23
PDF
Patient out-of-pocket savings with lower-dose trastuzumab.
2021
·
Marie S. Dreyer
, Alec Kacew
, et al.
·
Journal of Clinical Oncology
·
1
Biosimilar Development Considerations for Therapeutic Proteins With Limited Systemic Exposure: A Landscape Analysis and Pathway Evaluation
2026
·
Ting Wang
, Jenny Zheng
, et al.
·
Clinical Pharmacology & Therapeutics
PDF
Alternative trastuzumab dosing schedules and association with health care greenhouse gas emissions.
2023
·
Garth William Strohbehn
, Sofia Jacobson
, et al.
·
Journal of Clinical Oncology
Carbon emissions and non-biodegradable medical waste generation with alternative dosing strategies.
2022
·
Sofia I Jacobson
, Alec Kacew
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
6
Citation count:
48
H-index:
2
I10-index:
2
Year
Topic
Type